Overall verdict
Neutral
4.4/10
1-year performance
-29.68%
Score breakdown
Down 29.7% over 1 year, 1% of the 52-week range.
Strongest: Shareholder return 7.8/10. Weakest: Growth 0.0/10.
19 analysts, target +0.2% vs the price.
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The company home care cleaning and disinfecting products and laundry additives, skin sanitization and cleaning products, professional cleaning and disinfecting products, and professional food service products under the Clorox, Clorox2, Pine-Sol, Scentiva, Tilex, Liquid-Plumr, Formula 409, Purell, GOJO, CloroxPro, Clorox Healthcare, Hidden Valley, Poett, Clorinda, and Chux brands.
It also provides bags and wraps, cat litter, and grilling products under the Glad, Fresh Step, Scoop Away, Kingsford, and Ever Clean brands; and dressings, dips, seasonings, sauces, water-filtration products, and natural personal care products under the Brita and Burt's Bees brands. The company sells its products through mass retailers; grocery outlets; warehouse clubs; dollar stores; home hardware centers; drug, pet, and military stores; third-party and owned e-commerce channels; distributors; and other retail outlets through direct sales force. The company was founded in 1913 and is headquartered in Oakland, California.
Sector
Consumer Staples
Industry
Household Products
Primary listing
Nyse
United States
CEO
Linda Rendle
Founded
1913
Employees
9 200
Revenue / employee
730 435 USD
Next earnings
October 30, 2026 (estimated)
Institutional holders
- BlackRock, Inc.8.13%
- STATE STREET CORP6.82%
- VANGUARD CAPITAL MANAGEMENT LLC6.39%
- Invesco Ltd.4.86%
- VANGUARD PORTFOLIO MANAGEMENT LLC4.69%
- GEODE CAPITAL MANAGEMENT, LLC2.64%
- VAN ECK ASSOCIATES CORP2.41%
- MORGAN STANLEY1.82%
- MILLENNIUM MANAGEMENT LLC1.68%
- Other institutions45.09%
- Rest of the register15.46%
1045 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
128.90 USD
52-week low
81.73 USD
1-year performance
-29.68%
Declining
Year-to-date performance
-16.97%
Declining
Drawdown
-36.27%
Major drawdown
Position in the 52-week range
1% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned less, while shaking 1.7 times harder.
10,000 € placed at the end of September 2009 are worth today
| The Clorox | 35 062 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 1.7 times as much as the world ETF.
- Worst fall:-56 % between July 2020 and May 2026. 10,000 € placed at the top fell to 4 386 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
The Clorox earned less than the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- The Clorox: 35 062 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 104.01 USD - 106.99 USD (2 methods agree)
The price implies growth of 7.95% per year; the company grows at -2.93%.
Gross margin 41.9%, net margin 8.7%, ROIC 15.4%, ROE 285.6%.
Net margin
8.74%
Fair
Sector 8.17%|S&P 12.97%
Gross margin
41.95%
Fair
Return on equity (ROE)
285.64%
Exceptional
Sector 11.27%|S&P 16.52%
Return on invested capital (ROIC)
15.39%
Exceptional
Free cash flow margin (FCF)
6.03%
Low
Profit-to-cash conversion (FCF conversion)
0.69x
Fair
Margin stability
3.9 pts
Steady
Revenue to net income
Growth
0.0/10Revenue down 2.0% over 1 year, -1.8% a year over 5, EPS -2.9% a year over 5.
Revenue (trailing 12 months)
6.7Md USD
Revenue growth (1y)
-2.01%
Declining
Revenue growth (3y)
-9.05%
Declining
EPS growth (1y)
-50.12%
Declining
EPS CAGR (5y)
-2.93%
Declining
EPS revisions (3 months)
-7.75%
Sharply revised down
Valuation
4.8/10P/E 17.1x, forward P/E 14.4x, EV/EBITDA 12.3x. The multiple sits in the 10th percentile of its own 5-year history.
P/E (TTM)
17.1x
Fair
Sector 18.9x|S&P 23.0x
Forward P/E
14.4x
Fair
EV / EBITDA
12.3x
Expensive
Sector 10.0x|S&P 14.5x
PEG
—
Sector 0.79|S&P 0.86
Fair value (reverse DCF)
105.50 USD
Undervalued
P/E vs its own 5-year history
among the 10% lowest valuations
Far cheaper than usual
Market cap
10.2Md USD
Financial strength
1.3/10Cash covers 2.6% of the debt, net debt/EBITDA 4.8x.
Net debt / EBITDA
4.8x
Stretched
Gearing (net debt / equity)
2158.33%
Stretched
Cash
143M USD
Cash / market cap
1.41%
Stretched
Cash / total debt
2.56%
Stretched
Net debt
5.4Md USD
Equity
252M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 81.80 USD
- MM2090.27
- MM5097.38
- MM200102.00
- RSI 1428.1
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.38%
200-day average slope, 3 months
-5.10%
50-day average slope, 1 month
-1.96%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.84 % per day
Volatility change
-14.83%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 5.71 (7) | 5.79 (19) | 7 630 (16) | 1 397 (13) | 704 (6) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 16, 2026.
Same sub-industry: 34 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | HEN3 | 6.2 | 6.9 | 32.6Md USD | 15.8x | 9.4 % | — | 8.3 % | 0.2x | 7.1 % | 6.9 % | ||
| 2 | 8113 | 6.2 | 6.4 | 11.1Md USD | 25.6x | 6.7 % | 6.9 % | 8.1 % | -1.9x | 6.0 % | -2.5 % | ||
| 3 | RKT | 6.1 | 6.9 | 41.7Md USD | 11.3x | 21.2 % | 0.3 % | 22.4 % | 1.7x | 4.9 % | -12.9 % | ||
| 4 | CL | 5.8 | 5.3 | 68.5Md USD | 34.0x | 9.7 % | 4.9 % | 25.6 % | 1.5x | 5.6 % | 6.9 % | ||
| 5 | CHD | 5.7 | 5.3 | 22.8Md USD | 30.9x | 12.0 % | 1.6 % | 11.1 % | 1.5x | 4.9 % | 9.7 % | ||
| 6 | PG | 5.7 | 5.5 | 342Md USD | 22.3x | 18.4 % | 1.5 % | 20.7 % | 1.0x | 4.4 % | -4.2 % | ||
| 7 | KMB | 5.4 | 5.1 | 32.5Md USD | 16.6x | 10.2 % | 0.6 % | 21.1 % | 2.1x | 5.6 % | -21.1 % | ||
| 8 | ESSITY B | 5.3 | 5.4 | 17.9Md USD | 14.8x | 8.8 % | 2.6 % | 10.2 % | 1.1x | 6.2 % | 8.3 % | ||
| 9 | CLX | 4.4 | 4.3 | 10.2Md USD | 17.1x | 8.7 % | -2.0 % | 15.4 % | 4.8x | 4.0 % | -29.7 % |
